Trial Profile
A Phase II Study to Determine the Efficacy and Safety of High Dose Icotinib Combined With Stereotatic Radiosurgery for NSCLC Patients Harboring EGFR Mutation With Brain Metastases
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Dec 2022
Price :
$35
*
At a glance
- Drugs Icotinib (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Betta Pharmaceuticals Co Ltd
- 23 Jan 2019 Planned primary completion date changed from 1 Mar 2018 to 1 Dec 2021.
- 04 Apr 2016 New trial record